SYNCHRONIZE-CVOT
A Phase III, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity
- Stage
- followup
- Medicine
- BI 456906
- Population
- ASCVD
- Phase
- III
- First Patient In
- 15 February 2024
- Last Patient In
- 10 August 2024
- Last Patient Last Visit
- 1 July 2026
National Lead
dr. A. van Beek
Study Director
